316P Phase II study of ramucirumab and docetaxel for platinum-resistance NSCLC patients with malignant pleural effusion: Analysis of pleural effusion control rate

Abstract

The prognosis of non-small cell lung cancer (NSCLC) patients with malignant pleural effusion (MPE) due to pleural carcinomatosis is reported to be poor. Several studies suggested that anti-angiogenic treatments had the effect of decreasing vascular permeability and reducing pleural effusion. Ramucirumab (RAM), a vascular endothelial growth factor receptor-2 antibody that inhibits tumor angiogenesis, is widely used with docetaxel (DTX) after platinum doublet therapy failure. Presently, there is no data concerning the safety profile and efficacy of administering RAM+DTX to NSCLC patients with MPE.